NCT01370876 - Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2012

Conditions

Cancer of the Head and NeckNeoplasms, Head and Neck

Interventions

DRUG

Oxaliplatin

Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.

Trial Locations (1)

104

Taipei Mackay Memorial Hospital, Taipei